Dec 28, 2022

Biomica CEO to Attend the JP Morgan Healthcare Week in San Francisco between January 9-11, 2023

Rehovot, Israel – December 28, 2022 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced it will be in attendance at the Healthcare Week taking place together with the J.P. Morgan Healthcare Conference in San Francisco. The conference is one of the industry’s largest conferences of the year.

This follows Biomica’s recent successful financing round of $20 million, led by Shanghai Healthcare Capital, a leading Chinese private equity fund.

In attendance will be Dr. Elran Haber, CEO of Biomica, throughout the week from Monday, January 9 until Wednesday, January 11, 2023.

Dr. Haber will be available for one-on-one meetings throughout the week, and those interested should be in touch with Biomica’s investor or public relations team.

About Biomica

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN). For more information, please visit


Evogene Investor Contact: 
Kenny Green


Tel: +1 212 378 8040

Back to all News

Highlighted News About Biomica

ASCO 2024 logo
Apr 16, 2024

American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

We’re pleased to announce that Dr. Shiri Meshner, our VP of Research and Development, will be participating in the Pharmabiotic Conference 2024. She’ll be presenting alongside Claire Derlot, Chief Business Officer of Biose Industrie, on the topic “Biomica & Biose Industrie: The clinical journey of a multi-strain LBP”. Additionally, Dr. Meshner will contribute to a panel discussion focusing on Clinical Design & Methodology.